SCHEDULE: FMR LLC Maintains 8.3% Stake in PROCEPT BioRobotics

Sentiment:

Beneficial Ownership Report 8 January 2026 9:09 AM

📋All filings for Procept Biorobotics CORP

FMR LLC and Abigail P. Johnson reported an 8.3% beneficial ownership stake in PROCEPT BioRobotics Corp, holding over 4.6 million common shares as of December 31, 2025.

Summary

FMR LLC and Abigail P. Johnson collectively reported beneficial ownership of 4,653,110.77 shares of PROCEPT BIOROBOTICS CORP common stock.
This represents an 8.3% stake in the company's outstanding common stock.
FMR LLC holds sole voting power over 4,646,412.00 shares and sole dispositive power over 4,653,110.77 shares.
Abigail P. Johnson, as a control person of FMR LLC, is deemed to beneficially own the same 4,653,110.77 shares with sole dispositive power.
The filing is an Amendment No. 4 to a Schedule 13G, indicating a change in previously reported ownership or status.
The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant and sustained institutional investment by FMR LLC, a major asset manager, in PROCEPT BIOROBOTICS CORP. This suggests confidence in the company's long-term prospects, although the filing itself is a routine ownership disclosure and does not contain operational or financial performance data.

Positives

A significant institutional investor, FMR LLC, maintains a substantial 8.3% stake, indicating continued confidence in PROCEPT BIOROBOTICS CORP.
The filing confirms the shares are held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist intent.

Risks

No specific risks related to PROCEPT BIOROBOTICS CORP's operations or financial health are disclosed in this ownership filing.

Future Outlook

No forward-looking statements or guidance from PROCEPT BIOROBOTICS CORP are provided in this ownership filing.

Industry Context

This filing indicates continued institutional interest in the medical robotics sector, where PROCEPT BIOROBOTICS operates. Large investment firms like FMR LLC often hold significant stakes in companies they believe have strong growth potential or strategic importance within their respective industries.

Comparison to Industry Standards

An 8.3% stake by a major institutional investor like FMR LLC is a substantial position, often signaling a long-term strategic investment in a company within the medical technology or robotics space.
This level of ownership is common for large asset managers who invest across various sectors, including high-growth areas like surgical robotics, which has seen increased investor attention with companies like Intuitive Surgical (ISRG) and Stryker (SYK) leading the market.
While not a direct comparison of operational results, the sustained significant ownership by FMR LLC suggests a positive view of PROCEPT BIOROBOTICS's market position and future prospects relative to its peers in the competitive medical device industry.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Ownership Structure Disclosure	Disclosure of Abigail P. Johnson's role as Director, Chairman, and CEO of FMR LLC, and her family's predominant ownership of Series B voting common shares (49% voting power) within FMR LLC. This highlights the control structure of the reporting entity, FMR LLC.	NA	Provides transparency into the control structure of FMR LLC, the beneficial owner, but does not directly impact PROCEPT BIOROBOTICS CORP's corporate governance.

Stakeholder Impact

Shareholders: The continued significant stake by a major institutional investor like FMR LLC could be viewed positively, signaling institutional confidence and potentially contributing to share price stability.
Management: The "ordinary course of business" certification indicates FMR LLC is not seeking to influence or change control, which may provide stability for current management.

Key Dates

Date	Description
2023-01-03	Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries.
2023-01-10	Date of Schedule 13G filing by FMR LLC (accession number -23-000003) where FMR LLC's Power of Attorney is incorporated by reference.
2023-01-26	Effective date of Power of Attorney for Abigail P. Johnson.
2023-01-31	Date of Schedule 13G filing by FMR LLC (accession number -23-000038) where Abigail P. Johnson's Power of Attorney is incorporated by reference.
2025-12-31	Date of event which requires filing of this statement (reporting period end date).
2026-01-07	Signature date of the Schedule 13G Amendment No. 4 filing.

Recommendation

hold

This Schedule 13G filing is a routine disclosure of beneficial ownership by FMR LLC and Abigail P. Johnson, indicating a continued substantial stake of 8.3% in PROCEPT BIOROBOTICS CORP. The filing confirms that the shares are held in the ordinary course of business, without intent to influence control. While the sustained institutional interest is a positive signal, the filing itself does not provide new operational or financial performance data for PROCEPT BIOROBOTICS CORP that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on the company's fundamentals rather than this ownership disclosure alone.

Keywords

PROCEPT BIOROBOTICS CORP, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Fidelity, Medical Devices, Robotics

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.